[go: up one dir, main page]

AR075505A1 - Variantes de union a anti- albumina de suero mejoradas - Google Patents

Variantes de union a anti- albumina de suero mejoradas

Info

Publication number
AR075505A1
AR075505A1 ARP100100460A ARP100100460A AR075505A1 AR 075505 A1 AR075505 A1 AR 075505A1 AR P100100460 A ARP100100460 A AR P100100460A AR P100100460 A ARP100100460 A AR P100100460A AR 075505 A1 AR075505 A1 AR 075505A1
Authority
AR
Argentina
Prior art keywords
union
variations
serum albumin
improved serum
variants
Prior art date
Application number
ARP100100460A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR075505A1 publication Critical patent/AR075505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Variantes del dominio variable sencillo de inmunoglobulina anti-albumina de suero DOM7h-11; ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes.
ARP100100460A 2009-02-19 2010-02-17 Variantes de union a anti- albumina de suero mejoradas AR075505A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
AR075505A1 true AR075505A1 (es) 2011-04-06

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100460A AR075505A1 (es) 2009-02-19 2010-02-17 Variantes de union a anti- albumina de suero mejoradas

Country Status (25)

Country Link
US (3) US9534043B2 (es)
EP (3) EP2398826B1 (es)
JP (2) JP5759391B2 (es)
KR (1) KR101819754B1 (es)
CN (1) CN102405233B (es)
AR (1) AR075505A1 (es)
AU (1) AU2010215482B2 (es)
BR (1) BRPI1013341B1 (es)
CA (2) CA2767752C (es)
CL (1) CL2011002025A1 (es)
CO (1) CO6410311A2 (es)
DO (1) DOP2011000266A (es)
EA (1) EA028178B1 (es)
ES (2) ES2774192T3 (es)
HK (1) HK1247944A1 (es)
IL (1) IL214480A0 (es)
MA (1) MA33051B1 (es)
MX (1) MX2011008749A (es)
NZ (1) NZ595242A (es)
PE (1) PE20120001A1 (es)
SG (1) SG173489A1 (es)
TW (1) TW201042039A (es)
UY (1) UY32450A (es)
WO (1) WO2010094723A2 (es)
ZA (1) ZA201105657B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110137819A (ko) * 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
CA2774552A1 (en) * 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
ES2552177T3 (es) * 2009-10-27 2015-11-26 Glaxo Group Limited Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
BR112012029280A2 (pt) * 2010-05-20 2016-11-29 Glaxo Group Ltd variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2012069557A1 (en) * 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
WO2012072731A2 (en) 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
EP2670778A1 (en) 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
WO2017201340A2 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
AU2018280679B2 (en) * 2017-06-05 2025-04-24 Numab Therapeutics AG Novel anti-HSA antibodies
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007066109A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CA2683791A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2744588A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
UY32452A (es) 2009-02-19 2010-09-30 Glaxo Group Ltd Variantes de unión a anti-albúmina de suero mejoradas
BRPI1008014A2 (pt) * 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
EP2453920A2 (en) * 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
CA2774552A1 (en) * 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
JP2013528362A (ja) * 2010-04-21 2013-07-11 グラクソ グループ リミテッド 結合ドメイン

Also Published As

Publication number Publication date
US9534043B2 (en) 2017-01-03
MX2011008749A (es) 2011-09-06
AU2010215482B2 (en) 2014-02-13
ES2774192T3 (es) 2020-07-17
MA33051B1 (fr) 2012-02-01
ES2655071T3 (es) 2018-02-16
DOP2011000266A (es) 2011-12-31
EP2398826A2 (en) 2011-12-28
NZ595242A (en) 2013-11-29
CN102405233B (zh) 2014-11-26
KR101819754B1 (ko) 2018-01-18
US20110305696A1 (en) 2011-12-15
US10696738B2 (en) 2020-06-30
IL214480A0 (en) 2011-09-27
EP3330287A1 (en) 2018-06-06
BRPI1013341A2 (pt) 2016-10-11
PE20120001A1 (es) 2012-02-12
CA2767752A1 (en) 2010-08-26
CO6410311A2 (es) 2012-03-30
US20200283512A1 (en) 2020-09-10
JP2012517820A (ja) 2012-08-09
WO2010094723A2 (en) 2010-08-26
KR20110127223A (ko) 2011-11-24
EP3330287B1 (en) 2019-12-18
UY32450A (es) 2010-09-30
EP3656788A2 (en) 2020-05-27
CN102405233A (zh) 2012-04-04
ZA201105657B (en) 2012-04-25
EP3656788A3 (en) 2020-07-29
HK1247944A1 (en) 2018-10-05
WO2010094723A3 (en) 2011-04-21
CA2767752C (en) 2020-07-07
SG173489A1 (en) 2011-09-29
EA201171068A1 (ru) 2012-02-28
US20170298121A1 (en) 2017-10-19
CA3079184A1 (en) 2010-08-26
JP6100315B2 (ja) 2017-03-22
BRPI1013341B1 (pt) 2021-09-08
EP2398826B1 (en) 2017-10-25
CL2011002025A1 (es) 2012-04-09
JP2015204831A (ja) 2015-11-19
EA028178B1 (ru) 2017-10-31
TW201042039A (en) 2010-12-01
JP5759391B2 (ja) 2015-08-05
AU2010215482A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
AR075505A1 (es) Variantes de union a anti- albumina de suero mejoradas
DOP2011000269A (es) Variantes de union a anti-albumina de suero mejoradas
IN2012DN00640A (es)
EA201291009A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
CY1119287T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης-αντι-her2
CR20180393A (es) Conjugados de enzimas terapéuticas
MX384366B (es) Conjugados enlazadores auto-estabilizantes.
HK1249048A1 (zh) 靶向afp肽/mhc复合体的构建体及其用途
CO2018009533A2 (es) Conjugados de amanitina
EA201992456A2 (ru) Самостабилизирующиеся линкерные конъюгаты
NZ703581A (en) Anti-cd70 antibody drug conjugates
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
UA110470C2 (ru) Антидот антикоагулянта
UY35415A (es) Proteínas de unión a antígeno.
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
EA201390116A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
CR20110472A (es) Variantes de unión a anti-albumina de suero mejoradas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal